Immune checkpoint inhibitors (ICIs) have demonstrated significant clinical impact in
improving overall survival of several malignancies associated with poor outcomes; however …

Immune checkpoint inhibitors have dramatically improved cancer therapy for many patients.
These humanized monoclonal antibodies against various immune checkpoints (receptors …

Highlights•Recent experience with targeted anticancer drugs and immunotherapies suggest
the traditional approach of using the maximal tolerated dose (MTD) is not ideal.•Project …

The objectives of this analysis were to develop a population pharmacokinetics (PK) model of
durvalumab, an anti‐PD‐L1 antibody, and quantify the impact of baseline and time‐varying …

Immuno‐oncology works through activation of the patient's immune system against cancer,
with several advantages over other treatment approaches, including cytotoxic agents and …

Purpose To determine the exposure–response (ER) relationships between atezolizumab
exposure and efficacy or safety in patients with advanced non-small cell lung cancer …

Abstract Introduction Immune checkpoint inhibitors (ICIs) have become the standard of care
in the management of advanced non–small cell lung cancer (NSCLC). Nevertheless, only a …

Baseline patient characteristics and prognostic factors are important considerations in
oncology when evaluating the impact of immunogenicity on pharmacokinetics (PK) and …

Background Nivolumab is administered in a weight-based or fixed-flat dosing regimen. For
patients with non-small cell lung cancer (NSCLC), a potential exposure-response …

Immune checkpoint inhibitors are monoclonal antibodies (mAbs) directed against negative
immunologic regulators that are used to restore the immune response against cancer …